Dominik Bettinger1,2, David J Pinato3, Michael Schultheiss1, Rohini Sharma3, Lorenza Rimassa4, Tiziana Pressiani4, Michela E Burlone5, Mario Pirisi5, Masatoshi Kudo6, Joong Won Park7, Nico Buettner1, Christoph Neumann-Haefelin1, Tobias Boettler1, Nasrin Abbasi-Senger8, Horst Alheit9, Wolfgang Baus10, Oliver Blanck11, Sabine Gerum12, Mathias Guckenberger13, Daniel Habermehl14,15, Christian Ostheimer16, Oliver Riesterer13, Jörg Tamihardja17, Anca-Ligia Grosu18,19,20, Robert Thimme1, Thomas Baptist Brunner19,20,21, Eleni Gkika18. 1. Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2. Berta-Ottenstein Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom. 4. Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, Italy. 5. Department of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro,", Novara, Italy. 6. Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osakasayama, Japan. 7. Center for Liver Cancer, National Cancer Center Hospital, Goyang, Republic of Korea. 8. Department of Radiation Oncology, Friedrich-Schiller University Jena, Jena, Germany. 9. Radiotherapy Distler, Bautzen, Germany. 10. Department of Radiation Oncology, University Hospital of Cologne, Cologne, Germany. 11. Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. 12. Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich, Germany. 13. Department of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland. 14. Institute of Innovative Radiotherapy, Department of Radiation Science, Helmholtz Zentrum Munich, Munich, Germany. 15. Department of Radiation Oncology, Klinikum Rechts der Isar, TU Munich, Munich, Germany. 16. Department of Radiation Oncology, Martin Luther University Halle Wittenberg, Halle an der Saale, Germany. 17. Department of Radiation Oncology, University Hospital of Würzburg, Würzburg, Germany. 18. Department of Radiation Oncology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 19. German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. 20. German Cancer Research Center (DKFZ), Heidelberg, Germany. 21. Department of Radiotherapy, University of Magdeburg, Magdeburg, Germany.
Abstract
BACKGROUND AND AIMS: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. METHODS: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. RESULTS: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. CONCLUSIONS: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
BACKGROUND AND AIMS: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. METHODS: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. RESULTS: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. CONCLUSIONS: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: J Howell; D J Pinato; R Ramaswami; D Bettinger; T Arizumi; C Ferrari; C Yen; A Gibbin; M E Burlone; G Guaschino; L Sellers; J Black; M Pirisi; M Kudo; R Thimme; J-W Park; R Sharma Journal: Aliment Pharmacol Ther Date: 2017-03-02 Impact factor: 8.171
Authors: Yan Zhao; Guohong Cai; Lin Zhou; Lei Liu; Xingshun Qi; Ming Bai; Yongping Li; Daiming Fan; Guohong Han Journal: Asia Pac J Clin Oncol Date: 2013-05-29 Impact factor: 2.601
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien Journal: Nat Rev Gastroenterol Hepatol Date: 2020-07-17 Impact factor: 46.802
Authors: Luis A Pérez-Romasanta; Elisabet González-Del Portillo; Ana Rodríguez-Gutiérrez; Ángela Matías-Pérez Journal: Cancers (Basel) Date: 2021-01-07 Impact factor: 6.639
Authors: Thomas B Brunner; Dominik Bettinger; Michael Schultheiss; Lars Maruschke; Lukas Sturm; Nico Bartl; Ivana Koundurdjieva; Simon Kirste; Hannes P Neeff; Christian Goetz; Nils Henrik Nicolay; Gabriele Ihorst; Fabian Bamberg; Robert Thimme; Anca-Ligia Grosu; Eleni Gkika Journal: Front Oncol Date: 2021-03-19 Impact factor: 6.244
Authors: Jessica Howell; Amit Samani; Binish Mannan; Saur Hajiev; Leila Motedayen Aval; Rebecca Abdelmalak; Vincent C Tam; Dominik Bettinger; Robert Thimme; Tamar H Taddei; David E Kaplan; Max Seidensticker; Rohini Sharma Journal: Therap Adv Gastroenterol Date: 2022-09-30 Impact factor: 4.802